vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs -14.6%, a 27.6% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 0.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
AXSM vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $300.5M |
| Net Profit | $-28.6M | $39.0M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 13.0% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | -12.4% |
| EPS (diluted) | $-0.55 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $196.0M | $329.9M | ||
| Q3 25 | $171.0M | $330.2M | ||
| Q2 25 | $150.0M | $303.3M | ||
| Q1 25 | $121.5M | $318.5M | ||
| Q4 24 | $118.8M | $301.1M | ||
| Q3 24 | $104.8M | $305.5M | ||
| Q2 24 | $87.2M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | $-28.6M | $41.6M | ||
| Q3 25 | $-47.2M | $45.8M | ||
| Q2 25 | $-48.0M | $36.1M | ||
| Q1 25 | $-59.4M | $42.1M | ||
| Q4 24 | $-74.9M | $35.5M | ||
| Q3 24 | $-64.6M | $29.7M | ||
| Q2 24 | $-79.3M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 16.1% | ||
| Q3 25 | -27.0% | 18.4% | ||
| Q2 25 | -24.5% | 16.3% | ||
| Q1 25 | -46.9% | 18.1% | ||
| Q4 24 | -61.1% | 14.7% | ||
| Q3 24 | -59.8% | 13.9% | ||
| Q2 24 | -89.5% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -14.6% | 12.6% | ||
| Q3 25 | -27.6% | 13.9% | ||
| Q2 25 | -32.0% | 11.9% | ||
| Q1 25 | -48.9% | 13.2% | ||
| Q4 24 | -63.1% | 11.8% | ||
| Q3 24 | -61.7% | 9.7% | ||
| Q2 24 | -91.0% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $-0.55 | $0.68 | ||
| Q3 25 | $-0.94 | $0.74 | ||
| Q2 25 | $-0.97 | $0.57 | ||
| Q1 25 | $-1.22 | $0.65 | ||
| Q4 24 | $-1.54 | $0.55 | ||
| Q3 24 | $-1.34 | $0.46 | ||
| Q2 24 | $-1.67 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | $990.8M |
| Stockholders' EquityBook value | $88.3M | $2.2B |
| Total Assets | $689.8M | $15.7B |
| Debt / EquityLower = less leverage | — | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $88.3M | $2.2B | ||
| Q3 25 | $73.7M | $2.2B | ||
| Q2 25 | $73.1M | $2.2B | ||
| Q1 25 | $53.2M | $2.2B | ||
| Q4 24 | $57.0M | $2.2B | ||
| Q3 24 | $92.9M | $2.2B | ||
| Q2 24 | $102.9M | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $689.8M | $15.8B | ||
| Q3 25 | $669.3M | $15.6B | ||
| Q2 25 | $639.8M | $15.4B | ||
| Q1 25 | $596.7M | $15.8B | ||
| Q4 24 | $568.5M | $16.3B | ||
| Q3 24 | $561.5M | $15.9B | ||
| Q2 24 | $548.2M | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-38.7M | ||
| Q3 25 | $1.0M | $273.0M | ||
| Q2 25 | $-32.4M | $-234.6M | ||
| Q1 25 | $-43.4M | $5.8M | ||
| Q4 24 | $-26.2M | $273.9M | ||
| Q3 24 | $-18.6M | $515.6M | ||
| Q2 24 | $-30.1M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-55.5M | ||
| Q3 25 | $988.0K | $271.0M | ||
| Q2 25 | $-32.4M | $-234.6M | ||
| Q1 25 | $-43.7M | $5.0M | ||
| Q4 24 | $-26.2M | $266.8M | ||
| Q3 24 | $-18.7M | $513.8M | ||
| Q2 24 | $-30.2M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -16.8% | ||
| Q3 25 | 0.6% | 82.1% | ||
| Q2 25 | -21.6% | -77.4% | ||
| Q1 25 | -36.0% | 1.6% | ||
| Q4 24 | -22.1% | 88.6% | ||
| Q3 24 | -17.9% | 168.2% | ||
| Q2 24 | -34.6% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.1% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.3% | 0.3% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.1% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.93× | ||
| Q3 25 | — | 5.96× | ||
| Q2 25 | — | -6.50× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 7.71× | ||
| Q3 24 | — | 17.36× | ||
| Q2 24 | — | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
